

1 May 2019 12:00 BST

Transactions by Persons Discharging Managerial Responsibilities Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of \$0.25 each (Ordinary Shares) and American Depository Shares (ADSs) by certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) as set out below. Two ADSs are equivalent to one Ordinary Share.

PDMR	Position	Nature of the transaction	Quantity	Price
Pascal Soriot	Chief Executive Officer	Purchase of Ordinary Shares	17,100	GB£58.255
Philip Broadley	Non-Executive Director	Purchase of Ordinary Shares	520	GB£57.38
Sheri McCoy	Non-Executive Director	Purchase of ADSs	2,372	US\$38.1783
Sheri McCoy	Non-Executive Director	Purchase of ADSs	100	US\$38.172
Deborah DiSanzo	Non-Executive Director	Purchase of ADSs	1,000	US\$38.3056

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Pascal Soriot
2	Reason for the notification	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US\$0.25 each in AstraZeneca PLC GB0009895292				
b)	Nature of the transaction	Share purchase				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td><td>Volume(s)</td></tr> <tr> <td>GB£58.255</td><td>17,100</td></tr> </table>	Price(s)	Volume(s)	GB£58.255	17,100
Price(s)	Volume(s)					
GB£58.255	17,100					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	29 April 2019				
f)	Place of the transaction	XLON				

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Philip Broadley
2	Reason for the notification	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US\$0.25 each in AstraZeneca PLC GB0009895292				
b)	Nature of the transaction	Share purchase				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td><td>Volume(s)</td></tr> <tr> <td>GB£57.38</td><td>520</td></tr> </table>	Price(s)	Volume(s)	GB£57.38	520
Price(s)	Volume(s)					
GB£57.38	520					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	30 April 2019				
f)	Place of the transaction	XLON				

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Sheri McCoy
2	Reason for the notification	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depository Shares CUSIP: 046353108						
b)	Nature of the transaction	Purchase of AstraZeneca PLC American Depository Shares						
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td><td>Volume(s)</td></tr> <tr> <td>US\$38.1783</td><td>2,372</td></tr> <tr> <td>US\$38.175</td><td>100</td></tr> </table>	Price(s)	Volume(s)	US\$38.1783	2,372	US\$38.175	100
Price(s)	Volume(s)							
US\$38.1783	2,372							
US\$38.175	100							
d)	Aggregated information - Aggregated volume - Price	2,472 US\$38.178						
e)	Date of the transaction	29 April 2019						
f)	Place of the transaction	NYSE						

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Deborah DiSanzo
2	Reason for the notification	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	AstraZeneca PLC

b)	LEI	PY6ZZQWO2IZFZC3IOL08				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depository Shares CUSIP: 046353108				
b)	Nature of the transaction	Purchase of AstraZeneca PLC American Depository Shares				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td><td>Volume(s)</td></tr> <tr> <td>US\$38.3056</td><td>1,000</td></tr> </table>	Price(s)	Volume(s)	US\$38.3056	1,000
Price(s)	Volume(s)					
US\$38.3056	1,000					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	29 April 2019				
f)	Place of the transaction	NYSE				

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter [@AstraZeneca](https://twitter.com/AstraZeneca).

Media Relations

Gonzalo Viña	UK/Global	+44 203 749 5916
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Jennifer Hursit	UK/Global	+44 203 749 5762

Christina M Hägerstrand	Sweden	+46 8 552 53 106
Michele Meixell	US	+1 302 885 2677

Investor Relations

Thomas Kudsk Larsen		+44 203 749 5712
Henry Wheeler	Oncology	+44 203 749 5797
Christer Gruvris	BioPharma - Metabolism	Cardiovascular; +44 203 749 5711
Nick Stone	BioPharma - Respiratory; Renal	+44 203 749 5716
Josie Afolabi	Other	+44 203 749 5631
Craig Marks	Finance; Fixed Income	+44 7881 615 764
Jennifer Kretzmann	Retail Investors; Corporate Access	+44 203 749 5824
US toll-free		+1 866 381 72 77

Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.